Medical Products Supplies Companies

Avacta Unit 20, Ash Way Thorp Arch Estate, LS23 7FA Wetherby
United Kingdom of Great Britain and Northern Ireland
Telephone +44 1904 217070
affimers@avacta.com

Home

Product Categories

Product categories

03 Diagnostic Tests
03.02 Immunochemistry testing, immunology testing
03.02.01 Immuno assay testing

Immuno assay testing

03 Diagnostic Tests
03.02 Immunochemistry testing, immunology testing
03.02.02 Diagnostic rapid tests

Diagnostic rapid tests

Our products

Product category: Immuno assay testing, Diagnostic rapid tests
Anti-GST Affimer Reagent (L4-B1) Biotinylated
Catalogue Code: AVA00067-Biotin

Description: Anti-GST Affimer® (L4-B1) Biotinylated is an engineered alternative to anti-GST antibodies and equivalent aptamers

Tested in: ELISA

Reactivity: Recombinant GST

Size: 100µg

Product category: Immuno assay testing, Diagnostic rapid tests
Anti-GST Affimer Reagent (L4-B1)
Catalogue Code: AVA00067

Description: Affimer® (L4-B1) to GST is an engineered alternative to anti-GST antibodies and equivalent aptamers

Tested in: ELISA

Reactivity: Recombinant GST

Size: 100µg

Product category: Immuno assay testing, Diagnostic rapid tests
Anti-GST Affimer Reagent (L4-B1)
Catalogue Code: AVA00067

Description: Affimer® (L4-B1) to GST is an engineered alternative to anti-GST antibodies and equivalent aptamers

Tested in: ELISA

Reactivity: Recombinant GST

Size: 100µg

ad: contact information

About Us

Company details
Our mission is to shape the future of medicine by developing safe and efficacious drugs, and powerful research and diagnostic tools, based on our proprietary Affimer® platform

Avacta is developing novel cancer immunotherapies combining its two proprietary platforms – Affimer® biotherapeutics and tumour targeted chemotherapy. With this approach, the Company aims to address the lack of a durable response to current immunotherapies experienced by most patients.

The Affimer platform is an alternative to antibodies derived from a small human protein. Despite their shortcomings, antibodies currently dominate markets worth in excess of $100bn. Affimer technology has been designed to address many of these negative performance issues, principally: the time taken, and the reliance on an animal’s immune response, to generate new antibodies; poor specificity in many cases; large size and cost.

Avacta’s proprietary targeted chemotherapy platform, releases active drug only in the tumour, thereby limiting systemic exposure and improving the overall safety and therapeutic potential of these powerful anti-cancer treatments.

By combining these two platforms the Company is building a wholly owned pipeline of novel cancer therapies with the aim of creating effective treatments for all cancer patients including those who do not respond to existing immunotherapies. Avacta expects to take its first programme into the clinic in the first half of 2020.

Avacta has established drug development partnerships with pharma and biotech, including with Moderna Therapeutics Inc., and a deal with LG Chem worth up to $310m, and actively seeks to license its proprietary platforms in a range of therapeutic areas. The Company benefits from near-term revenues generated from Affimer reagents for diagnostics, bioprocessing and research, through a separate business unit.

ad: company